Gastrointestinal cancers (GC) are malignancies involving the gastrointestinal (GI) tract and accessory organs of the digestive system, including the pancreas, liver, and gall bladder. GC is one of the most common cancers and contributes to more cancer-related deaths than cancers of any other system in the human body. Causative factors of GC have been consistently attributed to infections, smoking, an unhealthy diet, obesity, diabetes, and genetic factors. More recently, aberrant epigenetic regulation of gene expression has emerged as a new, fundamental pathway in GC pathogenesis. In this review, we summarize the role of the macroH2A histone family in GI cell function and malignant transformation, and highlight how this histone family may open up novel biomarkers for cancer detection, prediction, and response to treatment.

Department of Biology Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Institute for Liver and Digestive Health Division of Medicine University College London London NW32PF UK

International Clinical Research Center St Anne's University Hospital 656 91 Brno Czech Republic

Zobrazit více v PubMed

Yang L., Fujimoto J., Qiu D., Sakamoto N. Trends in cancer mortality in the elderly in Japan, 1970–2007. Ann. Oncol. 2010;21:389–396. doi: 10.1093/annonc/mdp303. PubMed DOI

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Bedine M.S. Textbook of gastroenterology. Gastroenterology. 2000;118:984–985. doi: 10.1016/S0016-5085(00)70191-0. PubMed DOI

Pearson-Stuttard J., Zhou B., Kontis V., Bentham J., Gunter M.J., Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: A comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6:e6–e15. doi: 10.1016/S2213-8587(18)30150-5. PubMed DOI PMC

Arnold M., Sierra M.S., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–691. doi: 10.1136/gutjnl-2015-310912. PubMed DOI

Murphy N., Jenab M., Gunter M.J. Adiposity and gastrointestinal cancers: Epidemiology, mechanisms and future directions. Nat. Rev. Gastroenterol. Hepatol. 2018;15:659–670. doi: 10.1038/s41575-018-0038-1. PubMed DOI

Ulrich C.M., Himbert C., Holowatyj A.N., Hursting S.D. Energy balance and gastrointestinal cancer: Risk, interventions, outcomes and mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2018;15:683–698. doi: 10.1038/s41575-018-0053-2. PubMed DOI PMC

Forgacs I., Ashton R., Allum W., Bowley T., Brown H., Coleman M.P., Fitzgerald R., Glynn M., Hiom S., Jones R., et al. Conference report: Improving outcomes for gastrointestinal cancer in the UK. Front. Gastroenterol. 2018;9:49–61. doi: 10.1136/flgastro-2016-100713. PubMed DOI PMC

Vedeld H.M., Goel A., Lind G.E. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives. Semin. Cancer Biol. 2018;51:36–49. doi: 10.1016/j.semcancer.2017.12.004. PubMed DOI PMC

Palmirotta R., Lovero D., Cafforio P., Felici C., Mannavola F., Pelle E., Quaresmini D., Tucci M., Silvestris F. Liquid biopsy of cancer: A multimodal diagnostic tool in clinical oncology. Ther. Adv. Med. Oncol. 2018;10:1758835918794630. doi: 10.1177/1758835918794630. PubMed DOI PMC

Berdasco M., Esteller M. Clinical epigenetics: Seizing opportunities for translation. Nat. Rev. Genet. 2019;20:109–127. doi: 10.1038/s41576-018-0074-2. PubMed DOI

Buschbeck M., Hake S.B. Variants of core histones and their roles in cell fate decisions, development and cancer. Nat. Rev. Mol. Cell Biol. 2017;18:299–314. doi: 10.1038/nrm.2016.166. PubMed DOI

Thomas J.O., Kornberg R.D. An octamer of histones in chromatin and free in solution. Proce Natl. Acad. Sci. USA. 1975;72:2626–2630. doi: 10.1073/pnas.72.7.2626. PubMed DOI PMC

Ramachandran S., Henikoff S. Nucleosome dynamics during chromatin remodeling in vivo. Nucleus. 2016;7:20–26. doi: 10.1080/19491034.2016.1149666. PubMed DOI PMC

Talbert P.B., Henikoff S. Histone variants—Ancient wrap artists of the epigenome. Nat. Rev. Mol. Cell Biol. 2010;11:264–275. doi: 10.1038/nrm2861. PubMed DOI

Talbert P.B., Henikoff S. Environmental responses mediated by histone variants. Trends Cell Biol. 2014;24:642–650. doi: 10.1016/j.tcb.2014.07.006. PubMed DOI

Skene P.J., Henikoff S. Histone variants in pluripotency and disease. Development. 2013;140:2513–2524. doi: 10.1242/dev.091439. PubMed DOI

Filipescu D., Muller S., Almouzni G. Histone H3 variants and their chaperones during development and disease: Contributing to epigenetic control. Ann. Rev. Cell Dev. Biol. 2014;30:615–646. doi: 10.1146/annurev-cellbio-100913-013311. PubMed DOI

Gurard-Levin Z.A., Quivy J.P., Almouzni G. Histone chaperones: Assisting histone traffic and nucleosome dynamics. Ann. Rev. Biochem. 2014;83:487–517. doi: 10.1146/annurev-biochem-060713-035536. PubMed DOI

Costanzi C., Pehrson J.R. Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals. Nature. 1998;393:599–601. doi: 10.1038/31275. PubMed DOI

Rivera-Casas C., Gonzalez-Romero R., Cheema M.S., Ausio J., Eirin-Lopez J.M. The characterization of macroH2A beyond vertebrates supports an ancestral origin and conserved role for histone variants in chromatin. Epigenetics. 2016;11:415–425. doi: 10.1080/15592294.2016.1172161. PubMed DOI PMC

Chakravarthy S., Gundimella S.K., Caron C., Perche P.Y., Pehrson J.R., Khochbin S., Luger K. Structural characterization of the histone variant macroH2A. Mol. Cell. Biol. 2005;25:7616–7624. doi: 10.1128/MCB.25.17.7616-7624.2005. PubMed DOI PMC

Cantarino N., Douet J., Buschbeck M. MacroH2A—An epigenetic regulator of cancer. Cancer Lett. 2013;336:247–252. doi: 10.1016/j.canlet.2013.03.022. PubMed DOI

Lo Re O., Vinciguerra M. Histone MacroH2A1: A Chromatin Point of Intersection between Fasting, Senescence and Cellular Regeneration. Genes. 2017;8:367. doi: 10.3390/genes8120367. PubMed DOI PMC

Rasmussen T.P., Huang T., Mastrangelo M.A., Loring J., Panning B., Jaenisch R. Messenger RNAs encoding mouse histone macroH2A1 isoforms are expressed at similar levels in male and female cells and result from alternative splicing. Nucleic Acids Res. 1999;27:3685–3689. doi: 10.1093/nar/27.18.3685. PubMed DOI PMC

Hernandez-Munoz I., Lund A.H., van der Stoop P., Boutsma E., Muijrers I., Verhoeven E., Nusinow D.A., Panning B., Marahrens Y., van Lohuizen M. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc. Natl. Acad. Sci. USA. 2005;102:7635–7640. doi: 10.1073/pnas.0408918102. PubMed DOI PMC

Nusinow D.A., Hernandez-Munoz I., Fazzio T.G., Shah G.M., Kraus W.L., Panning B. Poly (ADP-ribose) polymerase 1 is inhibited by a histone H2A variant, MacroH2A, and contributes to silencing of the inactive X chromosome. J. Biol. Chem. 2007;282:12851–12859. doi: 10.1074/jbc.M610502200. PubMed DOI

Mietton F., Sengupta A.K., Molla A., Picchi G., Barral S., Heliot L., Grange T., Wutz A., Dimitrov S. Weak but uniform enrichment of the histone variant macroH2A1 along the inactive X chromosome. Mol. Cell. Biol. 2009;29:150–156. doi: 10.1128/MCB.00997-08. PubMed DOI PMC

Pazienza V., Panebianco C., Rappa F., Memoli D., Borghesan M., Cannito S., Oji A., Mazza G., Tamburrino D., Fusai G., et al. Histone macroH2A1.2 promotes metabolic health and leanness by inhibiting adipogenesis. Epigenet. Chromatin. 2016;9:45. doi: 10.1186/s13072-016-0098-9. PubMed DOI PMC

Soma A., Sato K., Nakanishi T. Visualization of inactive X chromosome in preimplantation embryos utilizing MacroH2A-EGFP transgenic mouse. Genesis. 2013;51:259–267. doi: 10.1002/dvg.22369. PubMed DOI

Borghesan M., Fusilli C., Rappa F., Panebianco C., Rizzo G., Oben J.A., Mazzoccoli G., Faulkes C., Pata I., Agodi A., et al. DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression. Cancer Res. 2016;76:594–606. doi: 10.1158/0008-5472.CAN-15-1336. PubMed DOI PMC

Lo Re O., Fusilli C., Rappa F., Van Haele M., Douet J., Pindjakova J., Rocha S.W., Pata I., Valcikova B., Uldrijan S., et al. Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma. Hepatology. 2017 doi: 10.1002/hep.29519. PubMed DOI

Kapoor A., Goldberg M.S., Cumberland L.K., Ratnakumar K., Segura M.F., Emanuel P.O., Menendez S., Vardabasso C., Leroy G., Vidal C.I., et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature. 2010;468:1105–1109. doi: 10.1038/nature09590. PubMed DOI PMC

Creppe C., Janich P., Cantarino N., Noguera M., Valero V., Musulen E., Douet J., Posavec M., Martin-Caballero J., Sumoy L., et al. MacroH2A1 regulates the balance between self-renewal and differentiation commitment in embryonic and adult stem cells. Mol. Cell. Biol. 2012;32:1442–1452. doi: 10.1128/MCB.06323-11. PubMed DOI PMC

Dardenne E., Pierredon S., Driouch K., Gratadou L., Lacroix-Triki M., Espinoza M.P., Zonta E., Germann S., Mortada H., Villemin J.P., et al. Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat. Struct. Mol. Biol. 2012;19:1139–1146. doi: 10.1038/nsmb.2390. PubMed DOI

Park S.J., Shim J.W., Park H.S., Eum D.Y., Park M.T., Mi Yi J., Choi S.H., Kim S.D., Son T.G., Lu W., et al. MacroH2A1 downregulation enhances the stem-like properties of bladder cancer cells by transactivation of Lin28B. Oncogene. 2016;35:1292–1301. doi: 10.1038/onc.2015.187. PubMed DOI PMC

Novikov L., Park J.W., Chen H., Klerman H., Jalloh A.S., Gamble M.J. QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation. Mol. Cell. Biol. 2011;31:4244–4255. doi: 10.1128/MCB.05244-11. PubMed DOI PMC

Sporn J.C., Kustatscher G., Hothorn T., Collado M., Serrano M., Muley T., Schnabel P., Ladurner A.G. Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene. 2009;28:3423–3428. doi: 10.1038/onc.2009.26. PubMed DOI

Jueliger S., Lyons J., Cannito S., Pata I., Pata P., Shkolnaya M., Lo Re O., Peyrou M., Villarroya F., Pazienza V., et al. Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. Epigenetics. 2016;11:709–720. doi: 10.1080/15592294.2016.1214781. PubMed DOI PMC

Rappa F., Greco A., Podrini C., Cappello F., Foti M., Bourgoin L., Peyrou M., Marino A., Scibetta N., Williams R., et al. Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma. PloS ONE. 2013;8:e54458. doi: 10.1371/annotation/b456329c-02fa-4055-afb8-2090cec17da6. PubMed DOI PMC

Ku G.Y., Ilson D.H. Preface on Esophagus Cancer. Chin. Clin. Oncol. 2017;6:44. doi: 10.21037/cco.2017.10.04. PubMed DOI

Brenner H., Rothenbacher D., Arndt V. Epidemiology of stomach cancer. Methods Mol. Biol. 2009;472:467–477. doi: 10.1007/978-1-60327-492-0_23. PubMed DOI

Li F., Yi P., Pi J., Li L., Hui J., Wang F., Liang A., Yu J. QKI5-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis. Oncotarget. 2016;7:32821–32834. doi: 10.18632/oncotarget.8739. PubMed DOI PMC

Keplinger K.M., Bloomston M. Anatomy and embryology of the biliary tract. Surg. Clin. North Am. 2014;94:203–217. doi: 10.1016/j.suc.2014.01.001. PubMed DOI

Boyer J.L. Bile formation and secretion. Compr. Physiol. 2013;3:1035–1078. doi: 10.1002/cphy.c120027. PubMed DOI PMC

Benavides M., Anton A., Gallego J., Gomez M.A., Jimenez-Gordo A., La Casta A., Laquente B., Macarulla T., Rodriguez-Mowbray J.R., Maurel J. Biliary tract cancers: SEOM clinical guidelines. Clin. Transl. Oncol. 2015;17:982–987. doi: 10.1007/s12094-015-1436-2. PubMed DOI PMC

European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. PubMed DOI

Global Burden of Disease Liver Cancer C., Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M.A., Allen C., Al-Raddadi R., Alvis-Guzman N., Amoako Y., et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–1691. doi: 10.1001/jamaoncol.2017.3055. PubMed DOI PMC

Sangiovanni A., Prati G.M., Fasani P., Ronchi G., Romeo R., Manini M., Del Ninno E., Morabito A., Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–1310. doi: 10.1002/hep.21176. PubMed DOI

Podrini C., Borghesan M., Greco A., Pazienza V., Mazzoccoli G., Vinciguerra M. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD) Curr. Pharm. Des. 2013;19:2737–2746. doi: 10.2174/1381612811319150009. PubMed DOI

Changolkar L.N., Singh G., Cui K., Berletch J.B., Zhao K., Disteche C.M., Pehrson J.R. Genome-wide distribution of macroH2A1 histone variants in mouse liver chromatin. Mol. Cell. Biol. 2010;30:5473–5483. doi: 10.1128/MCB.00518-10. PubMed DOI PMC

Guelen L., Pagie L., Brasset E., Meuleman W., Faza M.B., Talhout W., Eussen B.H., de Klein A., Wessels L., de Laat W., et al. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature. 2008;453:948–951. doi: 10.1038/nature06947. PubMed DOI

Fu Y., Lv P., Yan G., Fan H., Cheng L., Zhang F., Dang Y., Wu H., Wen B. MacroH2A1 associates with nuclear lamina and maintains chromatin architecture in mouse liver cells. Sci. Rep. 2015;5:17186. doi: 10.1038/srep17186. PubMed DOI PMC

Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., Mizuno K., Hasegawa G., Kishimoto H., Iizuka M., et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 2004;113:1774–1783. doi: 10.1172/JCI20513. PubMed DOI PMC

Borghesan M., Mazzoccoli G., Sheedfar F., Oben J., Pazienza V., Vinciguerra M. Histone variants and lipid metabolism. Biochem. Soc. Trans. 2014;42:1409–1413. doi: 10.1042/BST20140119. PubMed DOI

Sheedfar F., Vermeer M., Pazienza V., Villarroya J., Rappa F., Cappello F., Mazzoccoli G., Villarroya F., van der Molen H., Hofker M.H., et al. Genetic ablation of macrohistone H2A1 leads to increased leanness, glucose tolerance and energy expenditure in mice fed a high-fat diet. Int. J. Obes. 2015;39:331–338. doi: 10.1038/ijo.2014.91. PubMed DOI

Changolkar L.N., Costanzi C., Leu N.A., Chen D., McLaughlin K.J., Pehrson J.R. Developmental changes in histone macroH2A1-mediated gene regulation. Mol. Cell. Biol. 2007;27:2758–2764. doi: 10.1128/MCB.02334-06. PubMed DOI PMC

Boulard M., Storck S., Cong R., Pinto R., Delage H., Bouvet P. Histone variant macroH2A1 deletion in mice causes female-specific steatosis. Epigenet. Chromatin. 2010;3:8. doi: 10.1186/1756-8935-3-8. PubMed DOI PMC

Pazienza V., Borghesan M., Mazza T., Sheedfar F., Panebianco C., Williams R., Mazzoccoli G., Andriulli A., Nakanishi T., Vinciguerra M. SIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against lipid accumulation. Aging. 2014;6:35–47. doi: 10.18632/aging.100632. PubMed DOI PMC

Wan D., Liu C., Sun Y., Wang W., Huang K., Zheng L. MacroH2A1.1 cooperates with EZH2 to promote adipogenesis by regulating Wnt signaling. J. Mol. Cell Biol. 2017;9:325–337. doi: 10.1093/jmcb/mjx027. PubMed DOI

Podrini C., Koffas A., Chokshi S., Vinciguerra M., Lelliott C.J., White J.K., Adissu H.A., Williams R., Greco A. MacroH2A1 isoforms are associated with epigenetic markers for activation of lipogenic genes in fat-induced steatosis. FASEB J. 2015;29:1676–1687. doi: 10.1096/fj.14-262717. PubMed DOI

Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: Old questions and new insights. Science. 2011;332:1519–1523. doi: 10.1126/science.1204265. PubMed DOI PMC

Pehrson J.R., Changolkar L.N., Costanzi C., Leu N.A. Mice without macroH2A histone variants. Mol. Cell. Biol. 2014;34:4523–4533. doi: 10.1128/MCB.00794-14. PubMed DOI PMC

Sheedfar F., Di Biase S., Koonen D., Vinciguerra M. Liver diseases and aging: Friends or foes? Aging Cell. 2013;12:950–954. doi: 10.1111/acel.12128. PubMed DOI

Calvisi D.F., Ladu S., Gorden A., Farina M., Lee J.S., Conner E.A., Schroeder I., Factor V.M., Thorgeirsson S.S. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 2007;117:2713–2722. doi: 10.1172/JCI31457. PubMed DOI PMC

Sceusi E.L., Loose D.S., Wray C.J. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB. 2011;13:369–376. doi: 10.1111/j.1477-2574.2011.00303.x. PubMed DOI PMC

Lo Re O., Douet J., Buschbeck M., Fusilli C., Pazienza V., Panebianco C., Castracani C.C., Mazza T., Li Volti G., Vinciguerra M. Histone variant macroH2A1 rewires carbohydrate and lipid metabolism of hepatocellular carcinoma cells towards cancer stem cells. Epigenetics. 2018;13:829–845. doi: 10.1080/15592294.2018.1514239. PubMed DOI PMC

Helander H.F., Fandriks L. Surface area of the digestive tract—Revisited. Scand. J. Gastroenterol. 2014;49:681–689. doi: 10.3109/00365521.2014.898326. PubMed DOI

Li L., Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science. 2010;327:542–545. doi: 10.1126/science.1180794. PubMed DOI PMC

Yan K.S., Chia L.A., Li X., Ootani A., Su J., Lee J.Y., Su N., Luo Y., Heilshorn S.C., Amieva M.R., et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc. Natl. Acad. Sci. USA. 2012;109:466–471. doi: 10.1073/pnas.1118857109. PubMed DOI PMC

Powell A.E., Wang Y., Li Y., Poulin E.J., Means A.L., Washington M.K., Higginbotham J.N., Juchheim A., Prasad N., Levy S.E., et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell. 2012;149:146–158. doi: 10.1016/j.cell.2012.02.042. PubMed DOI PMC

Cedeno R.J., Nakauka-Ddamba A., Yousefi M., Sterling S., Leu N.A., Li N., Pehrson J.R., Lengner C.J. The histone variant macroH2A confers functional robustness to the intestinal stem cell compartment. PLoS ONE. 2017;12:e0185196. doi: 10.1371/journal.pone.0185196. PubMed DOI PMC

Yu D.H., Gadkari M., Zhou Q., Yu S., Gao N., Guan Y., Schady D., Roshan T.N., Chen M.H., Laritsky E., et al. Postnatal epigenetic regulation of intestinal stem cells requires DNA methylation and is guided by the microbiome. Genome Biol. 2015;16:211. doi: 10.1186/s13059-015-0763-5. PubMed DOI PMC

Testa U., Pelosi E., Castelli G. Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. Med. Sci. 2018;6:31. doi: 10.3390/medsci6020031. PubMed DOI PMC

Burt R.W., DiSario J.A., Cannon-Albright L. Genetics of colon cancer: Impact of inheritance on colon cancer risk. Ann. Rev. Med. 1995;46:371–379. doi: 10.1146/annurev.med.46.1.371. PubMed DOI

Lynch H.T., Smyrk T.C., Watson P., Lanspa S.J., Lynch J.F., Lynch P.M., Cavalieri R.J., Boland C.R. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review. Gastroenterology. 1993;104:1535–1549. doi: 10.1016/0016-5085(93)90368-M. PubMed DOI

Pearlman R., Frankel W.L., Swanson B., Zhao W., Yilmaz A., Miller K., Bacher J., Bigley C., Nelsen L., Goodfellow P.J., et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 2017;3:464–471. doi: 10.1001/jamaoncol.2016.5194. PubMed DOI PMC

Barzily-Rokni M., Friedman N., Ron-Bigger S., Isaac S., Michlin D., Eden A. Synergism between DNA methylation and macroH2A1 occupancy in epigenetic silencing of the tumor suppressor gene p16(CDKN2A) Nucleic Acids Res. 2011;39:1326–1335. doi: 10.1093/nar/gkq994. PubMed DOI PMC

Vardabasso C., Hasson D., Ratnakumar K., Chung C.Y., Duarte L.F., Bernstein E. Histone variants: Emerging players in cancer biology. Cell Mol. Life Sci. 2014;71:379–404. doi: 10.1007/s00018-013-1343-z. PubMed DOI PMC

De Barrios O., Gyorffy B., Fernandez-Acenero M.J., Sanchez-Tillo E., Sanchez-Moral L., Siles L., Esteve-Arenys A., Roue G., Casal J.I., Darling D.S., et al. ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1. Gut. 2017;66:666–682. doi: 10.1136/gutjnl-2015-310838. PubMed DOI

Sanchez-Tillo E., Liu Y., de Barrios O., Siles L., Fanlo L., Cuatrecasas M., Darling D.S., Dean D.C., Castells A., Postigo A. EMT-activating transcription factors in cancer: Beyond EMT and tumor invasiveness. Cell Mol. Life Sci. 2012;69:3429–3456. doi: 10.1007/s00018-012-1122-2. PubMed DOI PMC

Chen H., Ruiz P.D., McKimpson W.M., Novikov L., Kitsis R.N., Gamble M.J. MacroH2A1 and ATM Play Opposing Roles in Paracrine Senescence and the Senescence-Associated Secretory Phenotype. Mol. Cell. 2015;59:719–731. doi: 10.1016/j.molcel.2015.07.011. PubMed DOI PMC

Firestein R., Bass A.J., Kim S.Y., Dunn I.F., Silver S.J., Guney I., Freed E., Ligon A.H., Vena N., Ogino S., et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008;455:547–551. doi: 10.1038/nature07179. PubMed DOI PMC

Ohtsuka M., Ling H., Ivan C., Pichler M., Matsushita D., Goblirsch M., Stiegelbauer V., Shigeyasu K., Zhang X., Chen M., et al. H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-beta-Catenin Signaling in Colorectal Cancer. EBioMedicine. 2016;13:113–124. doi: 10.1016/j.ebiom.2016.10.026. PubMed DOI PMC

Morris K.V., Mattick J.S. The rise of regulatory RNA. Nat. Rev. Genet. 2014;15:423. doi: 10.1038/nrg3722. PubMed DOI PMC

Castle J.C., Zhang C., Shah J.K., Kulkarni A.V., Kalsotra A., Cooper T.A., Johnson J.M. Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat. Genet. 2008;40:1416–1425. doi: 10.1038/ng.264. PubMed DOI PMC

Yang G., Fu H., Zhang J., Lu X., Yu F., Jin L., Bai L., Huang B., Shen L., Feng Y., et al. RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology. 2010;138:231–240. doi: 10.1053/j.gastro.2009.08.001. PubMed DOI PMC

Yin D., Ogawa S., Kawamata N., Tunici P., Finocchiaro G., Eoli M., Ruckert C., Huynh T., Liu G., Kato M., et al. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol. Cancer Res. 2009;7:665–677. doi: 10.1158/1541-7786.MCR-08-0270. PubMed DOI

Hafner M., Landthaler M., Burger L., Khorshid M., Hausser J., Berninger P., Rothballer A., Ascano M., Jr., Jungkamp A.C., Munschauer M., et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010;141:129–141. doi: 10.1016/j.cell.2010.03.009. PubMed DOI PMC

Sporn J.C., Jung B. Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer. Am. J. Pathol. 2012;180:2516–2526. doi: 10.1016/j.ajpath.2012.02.027. PubMed DOI PMC

Warth A., Cortis J., Soltermann A., Meister M., Budczies J., Stenzinger A., Goeppert B., Thomas M., Herth F.J., Schirmacher P., et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer: A critical reappraisal of its prognostic role. Br. J. Cancer. 2014;111:1222–1229. doi: 10.1038/bjc.2014.402. PubMed DOI PMC

Hidalgo I.J., Raub T.J., Borchardt R.T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989;96:736–749. PubMed

Islami F., Ferlay J., Lortet-Tieulent J., Bray F., Jemal A. International trends in anal cancer incidence rates. Int. J. Epidemiol. 2017;46:924–938. doi: 10.1093/ije/dyw276. PubMed DOI

P.H.A.o. Canada . Section 5–5: Canadian Guidelines on Sexually Transmitted Infections—Management and Treatment of Specific Infections—Human Papillomavirus (HPV) infections—Canada.ca. Government of Canada; Ontario, ON, Canada: 2018.

Hoedema R.E. Anal Intraepithelial Neoplasia and Squamous Cell Cancer of the Anus. Clin. Colon. Rectal. Surg. 2018;31:347–352. doi: 10.1055/s-0038-1668104. PubMed DOI PMC

Uronis H.E., Bendell J.C. Anal cancer: An overview. Oncologist. 2007;12:524–534. doi: 10.1634/theoncologist.12-5-524. PubMed DOI

Hu W.H., Miyai K., Sporn J.C., Luo L., Wang J.Y., Cosman B., Ramamoorthy S. Loss of histone variant macroH2A2 expression associates with progression of anal neoplasm. J. Clin. Pathol. 2016;69:627–631. doi: 10.1136/jclinpath-2015-203367. PubMed DOI PMC

Deficiency of histone variant macroH2A1.1 is associated with sexually dimorphic obesity in mice

Histone Variant macroH2A1.1 Enhances Nonhomologous End Joining-dependent DNA Double-strand-break Repair and Reprogramming Efficiency of Human iPSCs

Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)

Loss of macroH2A1 decreases mitochondrial metabolism and reduces the aggressiveness of uveal melanoma cells

Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+ regulatory T cells activation

A Role for the Biological Clock in Liver Cancer

Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome